Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

122.41 +6.53 (+5.64%)
Official Closing Price Updated: 7:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,754,592
Open 120.55
Bid (Size) 122.30 (2,000)
Ask (Size) 123.00 (200)
Prev. Close 115.88
Today's Range 120.08 - 122.66
52wk Range 75.40 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.78%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
The healthcare sector outperformed the rest of the market over the past week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill

Performance

YTD
+15.0%
+15.0%
1 Month
+6.8%
+6.8%
3 Month
-1.1%
-1.1%
6 Month
+21.9%
+21.9%
1 Year
+57.8%
+57.8%

More News

Read More
Discover the top S&P500 movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
Merck & Co. Inc. (NYSE:MRK): A High Dividend Rating Backed by Strong Profitability and Financial Health ↗
Via Chartmill
News headline image
2 Reasons to Watch MRK and 1 to Stay Cautious
Via StockStory
Topics Stocks Supply Chain
News headline image
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
News headline image
1 Dividend ETF Quietly Outperforming the Market Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
2 Cash-Producing Stocks to Research Further and 1 Facing Challenges
Via StockStory
Topics Credit Cards
News headline image
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Dividend Stocks to Double Up On Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
From Merck & Co., Inc.
Via Business Wire
News headline image
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
The Top 5 Analyst Questions From Merck’s Q1 Earnings Call
Via StockStory
Topics Earnings
News headline image
Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
From Salesforce
Via Business Wire
News headline image
Tempus AI (TEM) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Monster Dividend Stocks That Could Pay You Through the Next Decade of Chaos ↗
Via The Motley Fool
Topics Artificial Intelligence
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter
Via StockStory
Top S&P500 movers in Thursday's after hours session ↗
Via Chartmill

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 122.41
When was Merck & Co last traded?
The last trade of Merck & Co was at 05/22/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 309.87B
How many shares of Merck & Co are outstanding?
Merck & Co has 310B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.